Valaciclovir for Epstein–Barr Virus Suppression in Patients With Moderate to Severe COPD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Valaciclovir for Epstein-Barr virus suppression in moderate-to-severe COPD (EViSCO): A randomised, double-blind, placebo-controlled trial
Chest 2023 Mar 31;[EPub Ahead of Print], DA Linden, H Guo-Parke, MC McKelvey, GG Einarsson, AJ Lee, DJ Fairley, V Brown, G Lundy, C Campbell, D Logan, M McFarland, D Singh, DF McAuley, CC Taggart, JC KidneyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.